- Asia Pacific
- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Recent Pfizer Press Releases
Pfizer Announces Positive Top-Line Results from Pivotal Phase 3 Maintenance Trial of Oral XELJANZ® (Tofacitinib Citrate) in Ulcerative Colitis7/28/16 4:10 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today top-line results from Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) Sustain, the third Phase 3 study of XELJANZ® (tofacitinib citrate) being investigated in patients with moderately to severely active ulcerative colitis (UC). OCTAVE Sustain is a 52 week study that evaluated oral tofacitinib 5 mg and 10 mg twice daily (BID) as a maintenance treatment in adult patients with moderately tomore...
Pfizer and Western Oncolytics Announce Immuno-Oncology Research Collaboration to Investigate Novel Oncolytic Virus Technology7/28/16 10:00 am EDT
Companies plan to advance Western Oncolytics’ lead preclinical therapy into human testing
Potential combination of WO-12 with Pfizer’s oncology pipeline could enhance therapeutic benefit in patientsNEW YORK & CLEVELAND--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Western Oncolytics announced today that they have entered into a development collaboration, license and option agreement to advance Western Oncolytics’ novel oncolytic vaccinia virus, WO-12. Oncolytic viruses are viruses engineered to kill cancer cells while sparing healthy cells, which subsequently elicits anti-cancer immune responses. This collaboration in oncolytic virus development adds another novel technologymore...
Pfizer Receives World Health Organization Prequalification for Multi-Dose Vial Presentation of Prevenar 13®7/19/16 8:00 am EDT
Designation Will Enable Increased Access to Vaccine in World’s Poorest CountriesNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the World Health Organization (WHO) has prequalified its four-dose, multi-dose vial (MDV) presentation of Prevenar 13®* (pneumococcal polysaccharide conjugate vaccine [13 – valent, adsorbed]). WHO prequalification allows for the global use of Prevenar 13® MDV by United Nations agencies and countries worldwide that require WHO prequalification. “It is unconscionable that children in developingmore...
Pfizer Announces the Publication of Final Results from Two Pivotal Phase 3 Studies of Crisaborole Topical Ointment in Patients with Mild to Moderate Atopic Dermatitis7/13/16 8:00 am EDT
Phase 3 Data Published in the Journal of the American Academy of DermatologyNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today the publication of findings from two pivotal Phase 3 studies of investigational crisaborole topical ointment 2% (formerly AN2728) in the online issue of the Journal of the American Academy of Dermatology. “Atopic dermatitis, or eczema, is a chronic, inflammatory skin disease that affects millions of children and adults. There have been no new therapies approved in the United States for people withmore...
7/12/16 4:04 pm EDT
Prevnar 13 is the only pneumococcal vaccine approved in the U.S. for patients 6 weeks through adulthoodNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) received U.S. Food and Drug Administration (FDA) approval for an expanded age indication to include adults 18 through 49 years of age, in addition to the already approved indication for adults 50 years and older, for active immunization for the prevention of pneumonia and invasive disease caused by 13 Streptococcusmore...
Pfizer Announces Positive Top-Line Results From Phase 3 S-TRAC Trial of SUTENT® (sunitinib) as Adjuvant Therapy in Patients at High Risk of Recurrent Renal Cell Carcinoma7/8/16 8:00 am EDT
S-TRAC is the First RCC Trial of a Tyrosine Kinase Inhibitor to Prolong Disease-Free Survival in the Adjuvant SettingNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the S-TRAC clinical trial (Sunitinib Trial in Adjuvant Renal Cancer), a Phase 3 study of SUTENT versus placebo in the adjuvant setting, met its primary endpoint of improving disease-free survival (DFS) as determined by blinded independent central review in patients with renal cell carcinoma (RCC) who are at high risk for recurrence after surgery. The S-TRAC trial is the first RCC trial of amore...
Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Trial to Evaluate Avelumab as First-line Treatment for Ovarian Cancer7/6/16 8:00 am EDT
DARMSTADT, Germany & NEW YORK--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) today announced the initiation of a Phase III study, JAVELIN Ovarian 100, to evaluate the efficacy and safety of avelumab* in combination with, and/or as follow-on (maintenance) treatment to, platinum-based chemotherapy in patients with locally advanced or metastatic disease (Stage III or Stage IV) with previously untreated epithelial ovarian cancer. JAVELIN Ovarian 100 is the first Phasemore...
- First Phase III trial evaluating the addition of an immune checkpoint inhibitor to standard of care in first-line ovarian cancer
- New investigational regimen will evaluate avelumab in extending progression-free survival in treatment-naïve women
Pfizer Advances Biosimilars Leadership with Investment in a New World-Class Global Biotechnology Center in China6/27/16 11:30 pm EDT
Pfizer’s state-of-the-art facility will foster the continued development of the biotechnology industry in China, further supporting National healthcare reformsNEW YORK & HANGZHOU, China--(BUSINESS WIRE)--Pfizer Inc. today announced that it will invest approximately USD$350 million in the development of a state-of-the-art Global Biotechnology Center at a ground-breaking ceremony in the Hangzhou Economic Development Area (HEDA) in China. This innovative facility will be Pfizer’s third biotechnology center globally and the first in Asia. It will ensure the local production of high-quality, affordable biosimilar medicines that willmore...
6/24/16 9:00 am EDT
Tender offer for all of the outstanding shares of Anacor common stock expired as scheduled immediately after 11:59 p.m., New York City time, on June 23, 2016
Pfizer and Anacor begin joint operations on June 24, 2016NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has completed its acquisition of Anacor Pharmaceuticals, Inc. Under the terms of the transaction, each outstanding share of Anacor common stock has been converted into the right to receive $99.25 net in cash (without interest but subject to required withholding of taxes). “Now that Anacor is part of Pfizer, we can accelerate our shared commitment to help patients with inflammatory disease,more...
6/23/16 4:00 pm EDTNEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 30-cent third-quarter 2016 dividend on the company’s common stock, payable September 1, 2016, to shareholders of record at the close of business on August 5, 2016. The third-quarter 2016 cash dividend will be the 311th consecutive quarterly dividend paid by Pfizer. Pfizer Inc. At Pfizer, we apply science and our global resources to bring therapies to people thatmore...